Angevin, E., Kelly, K., Heist, R., Morgensztern, D., Weekes, C., Bauer, T. M., … Strickler, J. (2016). First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. In Annals of Oncology (Vol. 27, p. vi118). https://doi.org/10.1093/annonc/mdw368.14

Angevin, E., K. Kelly, R. Heist, D. Morgensztern, C. Weekes, T. M. Bauer, R. K. Ramanathan, et al. “First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.” In Annals of Oncology, 27:vi118, 2016. https://doi.org/10.1093/annonc/mdw368.14.

Angevin E, Kelly K, Heist R, Morgensztern D, Weekes C, Bauer TM, et al. First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. In: Annals of Oncology. 2016. p. vi118.

Angevin, E., et al. “First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.” Annals of Oncology, vol. 27, 2016, p. vi118. Scopus, doi:10.1093/annonc/mdw368.14.

Angevin E, Kelly K, Heist R, Morgensztern D, Weekes C, Bauer TM, Ramanathan RK, Nemunaitis J, Fan X, Olyaie O, Parikh A, Reilly E, Afar D, Naumovski L, Strickler J. First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. Annals of Oncology. 2016. p. vi118.